Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
55
Recruiting, industry sponsors, Ophthalmology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed279
55 trials
Showing 1 to 25, recently updated first.
Sumitomo Pharma America, Inc.Industry
NCT06891885 · 12 participants (planned) · Start Apr 16, 2026 · Primary completion Oct 31, 2028
Drug: DSP-3077 Retinal Sheet Cohort 1; DSP-3077 Retinal Sheet Cohort 2 and 1 more · For: Retinitis Pigmentosa
Sites: Boston, Massachusetts; Minneapolis, Minnesota
AbbVieAbbVie (ABBV)
NCT06977724 · 36 participants (planned) · Start Aug 26, 2025 · Primary completion Mar 2029
Drug: ABBV-319 · For: Dry Eye Syndrome; Systemic Lupus Erythematosus
Sites: Margate, Florida; Tampa, Florida; Orland Park, Illinois · 9 sites in all
BlueRock TherapeuticsIndustry
NCT06789445 · 54 participants (planned) · Start Mar 10, 2025 · Primary completion Oct 2029
Drug: OpCT-001; OpCT-001 · For: Primary Photoreceptor Disease; Retinitis Pigmentosa (RP); Usher Syndrome and 6 more
Sites: Los Angeles, California; Miami, Florida; Philadelphia, Pennsylvania · 5 sites in all
Astellas Institute for Regenerative MedicineAstellas (ALPMY)
NCT03178149 · 42 participants (planned) · Start Jan 30, 2019 · Primary completion Dec 31, 2027
Drug: ASP7317; tacrolimus and 3 more · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 20 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07553429 · 49 participants (planned) · Start May 14, 2026 · Primary completion Mar 23, 2027
Drug: Low dose BI 3812465; Medium dose BI 3812465 and 1 more · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Scottsdale, Arizona; Arcadia, California · 29 sites in all
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
City TherapeuticsIndustry
NCT07836452 · 48 participants (planned) · Start Nov 4, 2026 · Primary completion Feb 2028
Drug: CITY-RBP4; Placebo · For: Stargardt Disease 1; STGD1; Healthy Volunteers
Sites: Melbourne, Australia
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07425522 · 93 participants (planned) · Start Apr 21, 2026 · Primary completion Nov 17, 2028
Drug: RO7823653; Faricimab · For: Diabetic Macular Edema
Sites: Peoria, Arizona; Beverly Hills, California; Walnut Creek, California · 12 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07649265 · 63 participants (planned) · Start Sep 24, 2026 · Primary completion Nov 20, 2028
Drug: HBM7020 · For: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Systemic Sclerosis and 1 more
Sites: Brisbane, Australia
Cellio Therapeutics IncIndustry
NCT07594236 · 15 participants (planned) · Start Apr 7, 2026 · Primary completion Dec 31, 2028
Drug: Injection · For: Geographic Atrophy; Stargardt Disease; RPE-mediated Maculopathy and 1 more
Sites: Beverly Hills, California; Palo Alto, California; Sacramento, California
Fujian Haixi Pharmaceuticals Co., Ltd.Industry
NCT07185841 · 198 participants (planned) · Start Jul 1, 2025 · Primary completion Jul 1, 2028
Drug: HX9428 tablet · For: Wet Age-related Macular Degeneration (AMD)
Sites: Beijing, China
Antengene Biologics LimitedIndustry
NCT07732309 · 149 participants (planned) · Start Sep 26, 2026 · Primary completion Dec 1, 2028
Drug: ATG-201 · For: Systemic Lupus Erythematosus; Systemic Sclerosis (SSc); Sjogren's Disease and 1 more
Sites: Bengbu, China; Hefei, China; Beijing, China · 22 sites in all
Astellas Institute for Regenerative MedicineAstellas (ALPMY)
NCT07734064 · 30 participants (planned) · Start Aug 14, 2026 · Primary completion Sep 30, 2029
Drug: ASP2020 · For: Stargardt Disease; Stargardt Macular Dystrophy; Stargardt-like Macular Dystrophy
Sites: Phoenix, Arizona; Southaven, Mississippi; Cincinnati, Ohio · 4 sites in all
Candid TherapeuticsIndustry
NCT07712939 · 105 participants (planned) · Start Jul 22, 2026 · Primary completion Mar 31, 2028
Drug: CND319 · For: Healthy Participants Study; Rheumatoid Arthritis; Sjogren's Syndrome
Sites: Melbourne, Australia
- A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07215234 · 104 participants (planned) · Start Oct 9, 2025 · Primary completion Oct 13, 2027
Drug: SAR446597; Sham Comparator · For: Geographic Atrophy
Sites: Peoria, Arizona; Scottsdale, Arizona; Beverly Hills, California · 35 sites in all
TherornaIndustry
NCT07413341 · 12 participants (planned) · Start Jan 22, 2026 · Primary completion May 1, 2027
Drug: TI-0032-III injection · For: Systemic Lupus Erythematosus (SLE); Sjogren's Syndrome (SS); Systemic Sclerosis (SSc) and 2 more
Sites: Shanghai, China
AAVantgarde Bio SrlIndustry
NCT07161544 · 75 participants (planned) · Start Sep 29, 2025 · Primary completion Jul 2032
Drug: AAVB-039 · For: Stargardt Disease
Sites: Phoenix, Arizona; Los Angeles, California; Jacksonville, Florida · 11 sites in all
- REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07675824 · 271 participants (planned) · Start Sep 8, 2026 · Primary completion Sep 14, 2029
Drug: REGN22530 · For: Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OHT)
Sites: Deerfield Beach, Florida
Octant, Inc.Industry
NCT07408232 · 18 participants (planned) · Start Mar 10, 2026 · Primary completion Nov 1, 2028
Drug: Phase 1b/2: Cohort 1 - OCT-980 Tablet; Phase 1b/2: Cohort 2 - OCT-980 Tablet and 3 more · For: Retinitis Pigmentosa
Sites: Portland, Oregon; Dallas, Texas
- A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
Biojiva LLCIndustry
NCT07029945 · 152 participants (planned) · Start Sep 29, 2026 · Primary completion Apr 2029
Drug: BRX011; Placebo · For: Geographic Atrophy
Sites: Gilbert, Arizona; Phoenix, Arizona; Hattiesburg, Mississippi · 17 sites in all
Therini Bio Pty LtdIndustry
NCT06701721 · 21 participants (planned) · Start Dec 20, 2024 · Primary completion Mar 31, 2027
Drug: THN391 · For: Diabetic Macular Edema; Diabetic Retinopathy
Sites: Parramatta, Australia; Sydney, Australia; Westmead, Australia · 10 sites in all
Arrowhead PharmaceuticalsIndustry
NCT07662096 · 84 participants (planned) · Start Jun 25, 2026 · Primary completion Jul 1, 2028
Drug: ARO-033; Placebo · For: Age-related Macular Degeneration
Sites: Auckland, New Zealand
SparingVisionIndustry
NCT07807111 · 27 participants (planned) · Start Oct 8, 2025 · Primary completion Mar 2032
Drug: SPVN20 (high dose); SPVN20 (medium dose) and 1 more · For: Retinitis Pigmentosa (RP); Rod Cone Dystrophy
Sites: Ghent, Belgium; Paris, France; Dublin, Ireland
Consun Pharmaceutical GroupIndustry
NCT07267026 · 84 participants (planned) · Start Dec 8, 2025 · Primary completion Apr 30, 2027
Drug: SK-09; Placebo · For: FSGS; MCD
Sites: Herston, Australia
VeonGen Therapeutics GmbHIndustry
NCT07002398 · 18 participants (planned) · Start Dec 23, 2024 · Primary completion Dec 2027
Drug: VG801 · For: Retinal Dystrophy Due to Biallelic ABCA4 Mutations; Stargardt Disease 1
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.